Remicade the dominant biologic drug for inflammatory bowel diseases.
By Joseph Hedden, Senior Analyst
16 September 2014
I am an analyst at Datamonitor Healthcare, having previously completed a PhD in Structural and Molecular Biology at Univ...
Read full bio
Remicade (infliximab; Johnson & Johnson/Merck/Mitsubishi Tanabe) is the dominant biologic drug for treatment of Crohn’s disease and ulcerative colitis. Across the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK) approximately 181,000 Crohn’s disease and 166,000 ulcerative colitis patients are using Remicade in 2014. This means that overall, about 22% of drug-treated Crohn’s disease and 10% of drug-treated ulcerative colitis patients are using Remicade at the present time.
Datamonitor Healthcare conducted primary research with a sample of 225 gastroenterologists (click here to view our treatment report) in the US, Japan and five major EU markets. Our data shows that Remicade becomes more relied upon later in the treatment algorithm for both Crohn’s disease and ulcerative colitis – generally as patients lose response to conventional therapies such as aminosalicylates, corticosteroids, and immunomodulators.
The largest threat to Remicade’s commercial success is impending competition with infliximab biosimilars. One biosimilar has already launched in some European markets and in Japan, and biosimilar incursion in the US is also expected further down the line. Remicade’s commercial success will also be affected by competition with other drugs. We believe the recently approved integrin inhibitor Entyvio will take some market share from Remicade, although Entyvio’s impact will likely be smaller than that of biosimilar competition.
Posted in Immunology and Inflammation.